न्यूबर्ग डायग्नोस्टिक्स हे आयपीएल(IPL) 2022 साठीचे अधिकृत निदान भागीदार बनले आहे

-

 न्यूबर्ग डायग्नोस्टिक्स हे आयपीएल(IPL) 2022 साठीचे अधिकृत निदान भागीदार बनले आहे 

मुंबई 24 मार्च 2022:-न्यूबर्ग डायग्नोस्टिक्स, भारतीय वंशाच्या शीर्ष 4 पॅथॉलॉजी लॅब चेन, आता आयपीएल 2022 साठी अधिकृत डायग्नोस्टिक पार्टनर बनले आहेत. राजस्थान रॉयल्स, चेन्नई सुपर किंग्ज आणि पंजाब किंग्ज हया आयपीएलच्या टीम साठी न्यूबर्गची अधिकृत निदान भागीदार म्हणून त्त्यांची नियुक्ती करण्यात आली आहे. 2022 हे दुसरे वर्ष आहे की आयपीएलने न्यूबर्ग डायग्नोस्टिक्ससोबत त्याचे निदान भागीदार म्हणून भागीदारी केली आहे.

प्रोटोकॉलनुसार सर्व खेळाडू, मॅनेजमेंट टीम, टेलिव्हिजन आणि ब्रॉडकास्टिंग क्रू, राज्य आणि केंद्रीय क्रिकेट बोर्ड सदस्य, ग्राउंड स्टाफ, हॉटेल स्टाफ आणि इव्हेंट मॅनेजमेंट टीम यांची चाचणी घेतली जात आहे. या चाचण्या विविध हॉटेल्समध्ये आयोजित केल्या जातील जिथे संघ बायो बबलमध्ये आणि स्टेडियममध्ये इतर कर्मचारी सदस्यांसाठी नियमित अंतराने आयोजित केले जातील.


या विकासावर बोलताना न्यूबर्ग डायग्नोस्टिक्स प्रायव्हेट लिमिटेडचे ​​ग्रुपचे उपाध्यक्ष श्री. ए गणेशन म्हणाले, “जगातील सर्वात मोठ्या क्रीडा स्पर्धांपैकी एक - आयपीएल 2022 शी निगडीत असल्याचा न्यूबर्ग समूहाला अभिमान वाटतो आणि या स्पर्धेचे सुरळीत आणि यशस्वी वर्तनासाठी गुणवत्ता चाचणी सुनिश्चित करेल."

Comments

Post a Comment

Popular posts from this blog

Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy

-
  Indegene acquires Trilogy Writing & Consulting GmbH,  a medical writing consultancy   India, March 27, 2024:  Indegene, a  digital-first, life sciences commercialization company , announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies. The acquisition by Indegene Ireland, a subsidiary of Indegene Limited, augments Indegene’s depth of clinical and regulatory writing expertise for market authorization applications globally.   Trilogy Writing & Consulting is a Germany, UK, and US-based, medical writing consultancy with know-how in the development and delivery of clinical, regulatory, safety, and medical content. It applies its expertise and unique approaches to deliver quality medical writing output. Trilogy has a proven track record of more than 22 years of providing medical writing services to the biopharmaceutica
Read more

TiEcon Mumbai 2023, brilliantly showcased revolutionary ideas & impactful solutions to build an Anti-Fragile and Sustainable India

-
Image
TiEcon Mumbai 2023, brilliantly showcased revolutionary ideas & impactful solutions to build an Anti-Fragile and Sustainable India Mumbai, 09 June 2023 : The 16th Edition of TiEcon Mumbai, organised by TiE Mumbai at Jio Convention Centre, BKC culminated on an enthusiastic note with a call to build an Anti-Fragile and Sustainable India. It kick-started with marquee speakers focusing on ways to accelerate growth, drive more intelligent engagement, make conscious choices and methods to empower sustainable business building ideas. Speaking at the summit, Ranu Vohra, President- TiE Mumbai said, “It was great to see the energy of the startup eco system at work at TiECon 2023. There were lively debates on Mumbai’s roadmap to becoming the startup hub, Gen AI and its role in India and the opportunities, thus created. The session on funding availability held out promise that as the startups become “anti-fragile” and focus on unit economics and profitability we should see a renewed incre
Read more

REC DECLARES ITS FINANCIAL RESULTS FOR Q2 & H1 FY24

-
REC DECLARES ITS FINANCIAL RESULTS FOR Q2 & H1 FY24   REC RECORDS ITS HIGHEST EVER QUARTERLY PROFIT AT ₹3,773 CRORE Mumbai/New Delhi, November 01, 2023: REC limited, a ‘Maharatna’ company under the administrative control of the Ministry of Power, Government of India, and registered with RBI as Non-Banking Finance Company (NBFC), Public Financial Institution (PFI) and Infrastructure Financing Company (IFC), has today reported its unaudited financial results (Standalone) for the 2nd Quarter and Half Year ended 30th September 2023. Key highlights are as under:  Operational and Financial Highlights –Q2 FY24 vs Q2 FY23 (Standalone) • Sanctions: ₹ 1,04,366 crore vs. ₹ 84,889 crore, up 23%, Renewable sector constitutes for 24% • Disbursements: ₹ 41,598 crore vs. ₹ 17,827 crore, up 133% • Interest Income on Loan Assets: ₹ 11,213 crore vs. ₹ 9,534 crore, up 18% • Net Profit: ₹ 3,773 crore vs. ₹ 2,728 crore, up 38% • Total Comprehensive Income: ₹ 4,188 crore vs. ₹ 1,915 crore, up 1
Read more